110 related articles for article (PubMed ID: 14630677)
1. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme.
van den Bent MJ; Grisold W; Frappaz D; Stupp R; Desir JP; Lesimple T; Dittrich C; de Jonge MJ; Brandes A; Frenay M; Carpentier AF; Chollet P; Oliveira J; Baron B; Lacombe D; Schuessler M; Fumoleau P; ;
Ann Oncol; 2003 Dec; 14(12):1732-4. PubMed ID: 14630677
[TBL] [Abstract][Full Text] [Related]
2. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group.
Briasoulis E; Pavlidis N; Terret C; Bauer J; Fiedler W; Schöffski P; Raoul JL; Hess D; Selvais R; Lacombe D; Bachmann P; Fumoleau P
Eur J Cancer; 2003 Nov; 39(16):2334-40. PubMed ID: 14556925
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: a study of the European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
Briasoulis E; Judson I; Pavlidis N; Beale P; Wanders J; Groot Y; Veerman G; Schuessler M; Niebch G; Siamopoulos K; Tzamakou E; Rammou D; Wolf L; Walker R; Hanauske A
J Clin Oncol; 2000 Oct; 18(20):3535-44. PubMed ID: 11032596
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors.
Shimizu T; Okamoto I; Tamura K; Satoh T; Miyazaki M; Akashi Y; Ozaki T; Fukuoka M; Nakagawa K
Cancer Chemother Pharmacol; 2010 Jan; 65(2):243-50. PubMed ID: 19479254
[TBL] [Abstract][Full Text] [Related]
5. Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group.
Giaccone G; Smit EF; de Jonge M; Dansin E; Briasoulis E; Ardizzoni A; Douillard JY; Spaeth D; Lacombe D; Baron B; Bachmann P; Fumoleau P;
Eur J Cancer; 2004 Mar; 40(5):667-72. PubMed ID: 15010066
[TBL] [Abstract][Full Text] [Related]
6. Glufosfamide: beta-D-Glc-IPM, D 19575.
Drugs R D; 2005; 6(1):49-52. PubMed ID: 15801867
[TBL] [Abstract][Full Text] [Related]
7. Glufosfamide as a new oxazaphosphorine anticancer agent.
Mazur L; Opydo-Chanek M; Stojak M
Anticancer Drugs; 2011 Jul; 22(6):488-93. PubMed ID: 21427562
[TBL] [Abstract][Full Text] [Related]
8. A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.
Ciuleanu TE; Pavlovsky AV; Bodoky G; Garin AM; Langmuir VK; Kroll S; Tidmarsh GT
Eur J Cancer; 2009 Jun; 45(9):1589-96. PubMed ID: 19188061
[TBL] [Abstract][Full Text] [Related]
9. Sagopilone (ZK-EPO, ZK 219477) for recurrent glioblastoma. A phase II multicenter trial by the European Organisation for Research and Treatment of Cancer (EORTC) Brain Tumor Group.
Stupp R; Tosoni A; Bromberg JEC; Hau P; Campone M; Gijtenbeek J; Frenay M; Breimer L; Wiesinger H; Allgeier A; van den Bent MJ; Bogdahn U; van der Graaf W; Yun HJ; Gorlia T; Lacombe D; Brandes AA
Ann Oncol; 2011 Sep; 22(9):2144-2149. PubMed ID: 21321091
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.
Galanis E; Jaeckle KA; Maurer MJ; Reid JM; Ames MM; Hardwick JS; Reilly JF; Loboda A; Nebozhyn M; Fantin VR; Richon VM; Scheithauer B; Giannini C; Flynn PJ; Moore DF; Zwiebel J; Buckner JC
J Clin Oncol; 2009 Apr; 27(12):2052-8. PubMed ID: 19307505
[TBL] [Abstract][Full Text] [Related]
11. Design of new oxazaphosphorine anticancer drugs.
Liang J; Huang M; Duan W; Yu XQ; Zhou S
Curr Pharm Des; 2007; 13(9):963-78. PubMed ID: 17430192
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of ifosfamide, carboplatin, and etoposide in patients with a first recurrence of glioblastoma multiforme.
Aoki T; Mizutani T; Nojima K; Takagi T; Okumura R; Yuba Y; Ueba T; Takahashi JA; Miyatake S; Nozaki K; Taki W; Matsutani M
J Neurosurg; 2010 Jan; 112(1):50-6. PubMed ID: 19538050
[TBL] [Abstract][Full Text] [Related]
14. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma.
Raymond E; Fabbro M; Boige V; Rixe O; Frenay M; Vassal G; Faivre S; Sicard E; Germa C; Rodier JM; Vernillet L; Armand JP
Ann Oncol; 2003 Apr; 14(4):603-14. PubMed ID: 12649109
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
Galanis E; Buckner JC; Maurer MJ; Kreisberg JI; Ballman K; Boni J; Peralba JM; Jenkins RB; Dakhil SR; Morton RF; Jaeckle KA; Scheithauer BW; Dancey J; Hidalgo M; Walsh DJ;
J Clin Oncol; 2005 Aug; 23(23):5294-304. PubMed ID: 15998902
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical and pharmacologic study of radiation therapy and carboxyamido-triazole (CAI) in adults with newly diagnosed glioblastoma multiforme.
Mikkelsen T; Lush R; Grossman SA; Carson KA; Fisher JD; Alavi JB; Rosenfeld S
Invest New Drugs; 2007 Jun; 25(3):259-63. PubMed ID: 17080256
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.
Reardon DA; Egorin MJ; Quinn JA; Rich JN; Gururangan S; Vredenburgh JJ; Desjardins A; Sathornsumetee S; Provenzale JM; Herndon JE; Dowell JM; Badruddoja MA; McLendon RE; Lagattuta TF; Kicielinski KP; Dresemann G; Sampson JH; Friedman AH; Salvado AJ; Friedman HS
J Clin Oncol; 2005 Dec; 23(36):9359-68. PubMed ID: 16361636
[TBL] [Abstract][Full Text] [Related]
18. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia.
Brandes AA; Basso U; Reni M; Vastola F; Tosoni A; Cavallo G; Scopece L; Ferreri AJ; Panucci MG; Monfardini S; Ermani M;
J Clin Oncol; 2004 May; 22(9):1598-604. PubMed ID: 15117981
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme.
Chang SM; Wen P; Cloughesy T; Greenberg H; Schiff D; Conrad C; Fink K; Robins HI; De Angelis L; Raizer J; Hess K; Aldape K; Lamborn KR; Kuhn J; Dancey J; Prados MD;
Invest New Drugs; 2005 Aug; 23(4):357-61. PubMed ID: 16012795
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study.
Cloughesy TF; Wen PY; Robins HI; Chang SM; Groves MD; Fink KL; Junck L; Schiff D; Abrey L; Gilbert MR; Lieberman F; Kuhn J; DeAngelis LM; Mehta M; Raizer JJ; Yung WK; Aldape K; Wright J; Lamborn KR; Prados MD
J Clin Oncol; 2006 Aug; 24(22):3651-6. PubMed ID: 16877733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
